Overview

This trial has been completed.

Condition atherosclerosis
Treatment in.pact admiral paclitaxel-eluting percutaneous transluminal angioplasty (pta) balloon catheter
Sponsor Medtronic Endovascular
Start date March 2014
End date August 2016
Trial size 143 participants
Trial identifier NCT02118532, IN.PACT SFA China

Summary

The purpose of this study is to confirm that the IN.PACT Admiral is safe and effective for the interventional treatment of new and non-stented restenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) in Chinese patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
in.pact admiral paclitaxel-eluting percutaneous transluminal angioplasty (pta) balloon catheter
IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic

Primary Outcomes

Measure
Primary effectiveness endpoint: Primary patency within 12 months post-index procedure
time frame: 12 months
Primary Safety Endpoint
time frame: 30 days post-index procedure

Secondary Outcomes

Measure
Major Adverse Events
time frame: 12 months
Death of any cause
time frame: 30 days, 6 and 12 months
Target Lesion Revascularization
time frame: 30 days, 6 and 12 months
Target Vessel Revascularization
time frame: 30 days, 6 and 12 months
Major target limb amputation
time frame: 30 days, 6 and 12 months
Thrombosis at the target lesion site
time frame: 30 days, 6 and 12 months
Time to first clinically-driven Target Lesion Revascularization
time frame: 12 months
Primary sustained clinical improvement
time frame: 6 and 12 months
Secondary sustained clinical improvement
time frame: 6 and 12 months
Duplex-defined binary restenosis (PSVR > 2.4) of the target lesion
time frame: 6 and 12 months
Duplex-defined binary restenosis (PSVR > 3.4) of the target lesion
time frame: 6 and 12 months
Walking capacity assessment
time frame: 30 days, 6 and 12 months
Walking distance
time frame: 30 days, 6 and 12 months
Quality of life assessment
time frame: 30 days, 6 and 12 months
Device success
time frame: Post procedure
Procedural success
time frame: Post procedure
Clinical success
time frame: Post procedure
Days of hospitalization due to the target lesion
time frame: 6 and 12 months

Eligibility Criteria

Male or female participants from 18 years up to 85 years old.

Inclusion Criteria: - Age ≥ 18 years and ≤ 85 years. - Subject with documented diagnosis of peripheral arterial disease (PAD) classified as Rutherford class 2-3-4 in the superficial femoral artery (SFA) and/or proximal popliteal artery (PPA) above the knee, located in the arterial segment starting at least 1 cm beyond the Common femoral artery (CFA) bifurcation between the superficial and profunda femoris arteries (proximal anatomical landmark to the distal P1 segment of the popliteal artery at the level of the proximal edge of the patella (distal anatomical landmark). - Target lesion consists of a single de novo or non-stented restenotic lesion (or a tandem lesion) or is a combination lesion - Reference vessel diameter ≥ 4 mm and ≤ 7 mm by visual estimate. - Subject able to walk without assistive devices (e.g. walker, cane). - If subject has ipsilateral/contralateral iliac disease that requires treatment during the index procedure - Angiographic evidence of adequate distal run-off to the foot (at least one native calf vessel [posterior tibial, anterior tibial, or peroneal arteries] is patent, defined as < 50% diameter stenosis). - Female subjects of childbearing potential must have a negative pregnancy test ≤ 7 days before index procedure and willing to use a reliable method of birth control for the duration of the study or must have documented adequate birth control. - Signed and dated Patient Informed Consent (PIC) form. - Understands and accepts the duration of the study and is able and willing to comply with all requirements, including follow-up visits and evaluations. - Life expectancy, in the Investigator's opinion, of at least 12 months. Exclusion Criteria: - In the investigator's opinion subject is unlikely to comply with the followup schedule. - Stroke or STEMI within the 3 months prior to index procedure. - Either local or systemic thrombolytic therapy within 48 hours prior to the index procedure. - Inability to tolerate oral anticoagulation therapy (blood thinners such as warfarin) while on concomitant dual antiplatelet therapy (DAPT). - Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant/anti-platelet therapies, and/or paclitaxel or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure. - Breastfeeding woman. - Chronic renal insufficiency with serum creatinine > 2.5 mg/dL within 14 days prior to index procedure. - WBC < 3.0 (3,000 cells/mm3) within 14 days prior to index procedure. - PLT count < 80,000 cells/mm3 or > 700,000 cells/mm3 within 14 days prior to index procedure. - Known or suspected active systemic infection evidenced by WBC > 14.0 (14000/mm3) within 14 days prior to index procedure. - Diagnosed with bleeding diatheses or hypercoagulable state. - Subject is enrolled in another investigational device, drug or biologic study or subject was previously enrolled to the IN.PACT SFA China trial. - Any major (e.g., cardiac. peripheral, abdominal) surgical procedure or intervention performed within 30 days prior to the index procedure. - Any major (e.g., cardiac. peripheral, abdominal) elective procedure or intervention within 30 days post index procedure. - Contralateral SFA/PPA disease requiring treatment in the same setting as index procedure. - Presence of additional lesions in the target vessel that require treatment during index procedure but do not meet the definitions of tandem lesions. - Target lesion is an in-stent or post-DEB restenosis or has been previously treated with bypass surgery. - Failure to successfully cross the target lesion with a guide wire - Lesion within or adjacent to an aneurysm. - Acute or sub-acute thrombus in the target vessel. - Angiographic evidence of severe calcification - Target lesion known in advance of enrollment to require treatment with alternative therapy such as drug-eluting stent (DES), drug-eluting balloon (DEB), laser, atherectomy, cryoplasty, re-entry devices, cutting/scoring balloon, brachytherapy. Use of embolic protection devices is also prohibited. - Pre-dilation resulted in a major ( ≥ Grade D) flow-limiting dissection (observed on 2 orthogonal views) or residual stenosis > 70% and translesional peak gradient > 10mm Hg.

Additional Information

Official title The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral™ Drug-Eluting Balloon in a Chinese Patient Population
Principal investigator Zhong Chen, Prof
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Medtronic Endovascular.